Latest Videos

CRISPR is revolutionizing the life sciences. Genome editing using RNA-programmable nucleases opens up a wealth of experimental options. At the same time, it makes creating new cell and animal models faster, easier and cheaper than in the past. Consequently, researchers in areas as diverse as cell/developmental biology, genetics or clinical research are turning to CRISPR as their method of choice.

Learn about how Personalized Medicine is changing how drugs are being developed and how healthcare is being delivered, and how Horizon is helping to enable this change.

Loss-of-function genetic screens with pooled sgRNA and shRNA libraries aid in discovery / prioritization of drug targets, understanding of disease progression and gene-disease associations, analysis of signal transduction pathways, characterization of the mechanisms for compounds, uncovering of synergistic gene interactions, and identification of markers of drug resistance and sensitivity. This webinar presents a comparison of loss-of-function genetic screens performed with CRISPR versus RNAi technology.

In this webinar, Dr Robert Williams, Chief Development Scientist, Cancer Research UK, will discuss how partnership between academia and industry can accelerate drug development.

Guangwen Chen, Professor, Dalian Institute Of Chemical Physics, speaking at Flow Chemistry Congress.

Lauren Drowley, Associate Principal Scientist, AstraZeneca, speaking at Stem Cells in Drug Discovery.

Andras Guttman, Adjunct Professor, Northeastern University, speaking at Flow Chemistry Congress.

I will discuss hurdles for the development of therapies for muscle disorders. I will present our platforms based upon iPS cells, inducible myogenesis and human artificial chromosomes. Extension of these technologies for tissue engineering and drug development will also be discussed.

Thatcher Root, Professor of Chemical and Biological Engineering, University of Wisconsin, speaking at Flow Chemistry Congress.